Interim Results

Clinical Computing PLC
29 August 2001



                            CLINICAL COMPUTING PLC

                             2001 INTERIM RESULTS



Clinical Computing PLC ('the Group'), the international developer of clinical
information systems for the healthcare market, announces Interim Results for
the six-month period ended 30 June 2001.  The Group trades through two
operating subsidiaries: Clinical Computing UK, Ltd. in the United Kingdom and
Europe and Clinical Computing, Inc. in the United States.



In his statement to shareholders, Chairman Michael Gordon said:

'The six months to 30 June 2001 has been a period of considerable investment,
preparing the Group for future growth and increasing our marketing presence in
both the UK and US.  With Clinical VisionTM sites now live in the US and UK,
the Group is focused on signing orders in the second half of the year and
rebuilding our backlog of business.'



Financial Overview

  * Turnover decreased marginally to £1.2m (2000: £1.3m)
  * Operating loss of £566,000 (2000: profit £84,000)
  * Loss after tax (nil) of £498,000 (2000: profit £157,000)
  * Loss per share (basic and diluted): 1.99p (2000: 0.6p earnings)
  * Sales and marketing costs increased to £394,000 (2000: £220,000)
  * Increased investment in Clinical Vision Framework; development of new
    applications
  * Cash position remains strong at £2.2m



Business Review

  * First Clinical Vision contract gain in US at Independent Dialysis
    Facility in Baltimore: now live
  * Negotiations nearing completion for supply of transplant application,
    demonstrating capabilities to expand into new markets
  * Clinical Vision framework positions the Group to benefit significantly
    from the anticipated future growth of the e-healthcare market



Outlook and Prospects

In his statement to shareholders, Chief Executive Jack Richardson, commenting
on the second half outlook, said:



'The Group is now better positioned with product and people to take advantage
of our chosen markets.



Our cash position provides us the means to continue our current course of
investing in Clinical Vision as well as expanding our marketing presence in
both the UK and US.



The Group is confident that expanding our presence into wider markets through
new applications will enable the Group to better exploit opportunities for
future growth.'


Contacts:
Jack Richardson , Chief Executive                      [phone]
Joseph Marlovits, Finance Director                     020 8380 4400
Peter Binns, Binns & Co PR Ltd                         020 7786 9600




Chairman's and Chief Executive's Statement



Introduction

The six months to 30 June 2001 has been a period of considerable investment,
preparing the Group for future growth and increasing our marketing presence in
both the UK and US.  During the period, the Group has focused on securing US
reference sites for Dialysis and Transplant, and building our pipeline of
order opportunities.  In June, the Group announced the first US contract for
Clinical VisionTM.  With Clinical Vision sites now live in the US and UK, the
Group is focused on signing orders in the second half of the year and
rebuilding our backlog of business.





Results

During the period under review, turnover decreased 12% to £1,176,000 (2000: £
1,331,000).  The majority of the decrease is attributable to a reduction in
maintenance revenue on legacy systems.  The Group produced an operating loss
of £566,000, which together with net interest income of £68,000 resulted in a
loss on ordinary activities of £498,000.  Cost of sales has increased 14% due
to increased investment in the Clinical Vision framework and development of
new applications.  Distribution costs have increased 79% as a result of the
Group rebuilding its sales and marketing presence in the US and the UK.  The
combined cost increases for product development and expansion of sales
activities represent 50% of the operating loss incurred in the first half of
2001.  Other operating income, which reflects exchange gains or losses on
certain monetary assets of the Group denominated in foreign currencies, has
decreased 69% when compared to the prior year.





Business Overview

In June, the Group announced its first US contract for Clinical Vision with
Independent Dialysis Facilities in Baltimore, Maryland USA.  Independent
Dialysis Facilities is a 10-facility dialysis chain, and will collaborate with
us to produce a case study for marketing Clinical Vision.  The site is now
live and serves as our premier Clinical Vision reference site in the US.



The Group is further pleased to announce that we are in final negotiations to
supply a transplant application that begins Clinical Vision's expansion into
broader markets.  The application will provide for solid organ transplants,
and will include modules for heart, lung, liver, kidney, small bowel and
pancreas transplantation.  The first beta module is scheduled for delivery by
31 December 2001, with subsequent deliveries of modules to follow in 2002.



Clinical Vision is the result of a four-year development effort and like its
predecessor, PROTONTM, has been developed to deliver future-proofed
technologies that are ahead of its competition.  It allows for scalability
across large organizations such as the largest dialysis chain customers, and
major hospitals running multiple Clinical Vision applications.

Healthcare providers such as hospitals, medical centres, and laboratories, are
moving to Internet-delivered systems.  The conversion of the healthcare
business and patient-centered processes to electronic record keeping, known as
e-healthcare, is an ever-expanding industry.  Clinical Vision has been
developed to meet the needs of e-healthcare and our investment in the Clinical
Vision framework positions us to share in this market.



Outlook

The Group expects turnover to remain stable through the rest of year.  We
anticipate that less than 50% of new orders signed in the second half will
translate to turnover before year-end due to the nature of our customer base
and the Group's revenue recognition policy.  However, the order backlog built
during the second half of the year will become the building block for 2002.
The Group will continue forward with the investment in new applications for
Clinical Vision and with the expansion of our UK and US marketing efforts.



The Group continues to maintain a strong cash position and ended the period
with cash and investments of £2,161,000.  During the period £455,000 of cash
was used to support operations, and a similar cash requirement is expected for
the second half of the year.  Our cash position provides us the means to
continue investing in Clinical Vision and expanding our marketing presence.



With Clinical Vision sites now live in both the US and the UK, the Group
believes that investment in our marketing presence will allow us to maximise
potential orders of this product.  The Group is confident that expanding into
broader markets with new applications will lead to future growth.







Michael Gordon                       Jack Richardson
Chairman                             Chief Executive

29 August 2001




Unaudited Consolidated Profit and Loss Account

Six Months Ended 30 June 2001


                                                        Six      Six     Year
                                                     Months   Months    ended
                                                      ended    ended       31
                                                    30 June  30 June December
                                                       2001     2000     2000
                                                      £'000    £'000    £'000

Turnover                                              1,176    1,331    2,259


Cost of sales

Research & development                                  565      507    1,014
Other                                                   330      279      585
                                                 ---------- --------- ----------
                                                      (895)    (786)  (1,599)
                                                 ---------- --------- ----------

Gross profit                                            281      545      660


Distribution costs                                      394      220      476
Administrative expenses                                 516      444      924
Other operating income                                 (63)    (203)    (253)
                                                 ---------- ---------- ---------
                                                      (847)    (461)  (1,147)
                                                 ---------- ---------- ---------

Operating (loss) profit                               (566)       84    (487)

Net interest receivable                                  68       73      158
                                                 ---------- ---------- ---------

(Loss) profit on ordinary activities before and
after taxation                                        (498)      157    (329)
                                                 ---------- ---------- ---------

Basic and diluted (loss) earnings per share
(Note 3)                                            (1.99p)     0.6p   (1.3p)
                                                 ---------- ---------- ---------




All results are derived from continuing operations.



Unaudited Consolidated Statement of Total Recognised Gains and Losses

Six Months Ended 30 June 2001


                                       Six Months     Six Months           Year
                                            ended          ended          ended
                                          30 June        30 June    31 December

                                             2001           2000           2000
                                            £'000          £'000          £'000

(Loss) profit for the period                (498)            157          (329)
Loss on foreign currency translation         (54)           (33)           (49)
                                       ----------     ----------     ----------
Total recognised gains and losses           (552)            124          (378)

                                       ----------     ----------     ----------



Unaudited Consolidated Balance Sheet

30 June 2001


                                           30 June       30 June    31 December
                                              2001          2000           2000
                                             £'000         £'000          £'000

Tangible fixed assets                          329           313            338

                                        ----------    ----------     ----------
Current assets
Stocks                                          41            41             41
Debtors                                        506           727            568
Cash at bank and in hand
(including short term deposits)              1,657         2,957          2,600
Current asset investment                       504             -              -
                                        ----------    ----------     ----------
                                             2,708         3,725          3,209
                                        ----------    ----------     ----------

Creditors: Amounts falling due within one year

Deferred income                                743           727            645
Other                                          247           216            303
                                        ----------    ----------     ----------
                                               990           943            948
                                        ----------    ----------     ----------
Net current assets                           1,718         2,782          2,261

                                        ----------    ----------     ----------

Net assets                                   2,047         3,095          2,599

                                        ----------    ----------     ----------

Capital and reserves

Called-up share capital                      1,254         1,254          1,254
Share premium account                        4,248         4,248          4,248
Profit and loss account                    (3,455)       (2,407)        (2,903)
                                        ----------    ----------     ----------

Shareholders' funds - all equity             2,047         3,095          2,599

                                        ----------    ----------     ----------



Unaudited Consolidated Cash Flow Statement

Six months Ended 30 June 2001


                                                        Six       Six      Year
                                                     Months    Months     ended
                                                      ended     ended        31
                                                    30 June   30 June  December
                                                       2001      2000      2000
                                                      £'000     £'000     £'000

Net cash (outflow) inflow from operating
activities (Note 4)                                   (455)        48     (147)

Returns on investments                                   68        73       158
Capital expenditure                                    (59)      (31)     (133)
                                                  --------- ---------- ---------

                                                          9        42        25
                                                  --------- ---------- ---------


Cash (outflow) inflow before management of liquid
resources                                             (446)        90     (122)

Management of liquid resources                           54     (345)       447
                                                  --------- --------- ----------

(Decrease) increase in cash                           (392)     (255)       325
                                                  --------- --------- ----------



Reconciliation of net cash flow to movement in net funds


(Decrease) increase in cash in the period
(including overdrafts)                                (392)     (255)      335
                                                   --------- --------- ---------

Cash (outflow) inflow from movement in liquid
resources                                              (54)       345    (447)
                                                   --------- --------- ---------


Change in net funds resulting from cash flows         (446)        90    (112)
Exchange movement                                        29        85     (72)
Other non-cash changes                                 (20)        -        -
                                                  ---------- --------- ---------


Movement of net funds in the period                   (437)      175     (184)
Net funds at beginning of period                      2,598    2,782     2,782
                                                  ---------- --------- ---------


Net funds at end of period                            2,161    2,957     2,598

                                                  ---------- --------- ---------



Notes:


1.  The interim results for the six months ended 30 June 2001, set out here,
    have been complied in accordance with applicable accounting standards and
    on a basis consistent with the most recent set of annual financial
    statements.  They have been reviewed by our auditors, Arthur Andersen, and
    a copy of their report is attached.  The auditors discussed their review
    and findings with the Audit Committee.


2.  The above financial information does not constitute statutory financial
    statements within the meaning of Section 240 of the Companies Act 1985.
    Group statutory financial statements for the year ended 31 December 2000,
    which included an unqualified audit report, have been filed with the
    Registrar of Companies.


3.  Basic earnings per share has been calculated on the basis of the weighted
    average number of shares in issue, being 25,080,310 for the six months
    ended 30 June 2001, six months ended 30 June 2000, and for the year ended
    31 December 2000.



    Diluted earnings per share has been calculated on the basis of the weighted
    average number of shares in issue, being 25,080,310 for the six months
    ended 30 June 2001, 25,426,926 for the six months ended 30 June 2000, and
    25,321,638 for the year ended 31 December 2000.


4.  Reconciliation of operating (loss) profit to operating cash flows


                                                  30 June    30 June         31
                                                                       December
                                                     2001       2000       2000
                                                    £'000      £'000      £'000

Operating (loss) profit                             (566)         84      (486)
Depreciation charge                                    79         75        154
Loss on disposal of fixed assets                        -          -          1
Decrease in debtors                                    78         48        212
Decrease in creditors                                (70)      (159)       (33)
Loss on current asset investment                       24          -          -
Share options issued at a discount                      -          -          5
                                               ---------- ---------- ----------
Net cash (outflow) inflow from operating
activities                                          (455)         48      (147)
                                               ---------- ---------- ----------





5.    Analysis and reconciliation of net funds



                                                               Other
                        31 December       Cash   Exchange   non-cash    30 June
                               2000       flow   movement    changes       2001
                              £'000      £'000      £'000      £'000      £'000

Cash at bank and in             465      (394)          6          -         77
hand
Overdraft                       (2)          2          -          -          -
                         ----------  --------- ---------- ---------- ----------
                                463      (392)          6          -         77
Short term deposits           2,135      (575)         20          -      1,580
Current asset                     -        521          3       (20)        504
investment
                         ----------  --------- ---------- ---------- ----------
Net funds                     2,598      (466)         29       (20)      2,161

                         ----------  --------- ---------- ---------- ----------





6.  Copies of this interim report will be sent to shareholders and are
    available from the Company's head office at 4 Thameside Centre, Kew Bridge
    Road, Brentford, Middlesex, TW8 OHF.






INDEPENDENT REVIEW REPORT TO CLINICAL COMPUTING PLC



Introduction



We have been instructed by the company to review the financial information for
the six months ended 30 June 2001, which comprises the profit and loss
account, the statement of total recognised gains and losses, the balance
sheet, the cash flow statement and the related notes. We have read the other
information contained in the interim report and considered whether it contains
any apparent misstatements or material inconsistencies with the financial
information.



Directors' responsibilities



The interim report, including the financial information contained therein, is
the responsibility of, and has been approved by, the directors.  The directors
are responsible for preparing the interim report in accordance with the
Listing Rules of the Financial Services Authority which require that the
accounting policies and presentation applied to the interim figures should be
consistent with those applied in preparing the preceding annual accounts
except where any changes, and the reasons for them, are disclosed.



Review work performed



We conducted our review in accordance with guidance contained in Bulletin 1999
/4 issued by the Auditing Practices Board for use in the United Kingdom.  A
review consists principally of making enquiries of group management and
applying analytical procedures to the financial information and underlying
financial data and based thereon, assessing whether the accounting policies
and presentation have been consistently applied unless otherwise disclosed.  A
review excludes audit procedures such as tests of controls and verification of
assets, liabilities and transactions.  It is substantially less in scope than
an audit performed in accordance with United Kingdom Auditing Standards and
therefore provides a lower level of assurance than an audit.  Accordingly, we
do not express an audit opinion on the financial information.



Review conclusion



On the basis of our review we are not aware of any material modifications that
should be made to the financial information as presented for the six months
ended 30 June 2001.



Arthur Andersen

Chartered Accountants

Betjeman House

104 Hills Road

Cambridge CB2 1LH




29 August 2001